Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Michael Tilby.

Newcastle AuthorsTitleYearFull text
Nidal Boulos
Dr Michael Tilby
Professor Deborah Tweddle
Professor John Lunec
Identification and characterisation of STMN4 and ROBO2 gene involvement in neuroblastoma cell differentiation2013
Dr Ian Cowell
Dr Michael Tilby
Professor Caroline Austin
An overview of the visualisation and quantitation of low and high MW DNA adducts using the trapped in agarose DNA immunostaining (TARDIS) assay2011
Professor Caroline Austin
Dr Ian Cowell
Dr Michael Tilby
Visualisation and quantitation of DNA adducts using the Trapped in Agarose DNA immunostaining (TARDIS) assay2010
Dr Michael Tilby
Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells2009
Dr Michael Tilby
Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents2009
Dr Celine Roche
Professor Steve Wedge
Professor Herbie Newell
Dr Michael Tilby
The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK22009
Andrew Jobson
Dr Elaine Willmore
Dr Michael Tilby
Professor Caroline Austin
Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases2008
Dr Michael Tilby
Substituted β-cyclodextrin and calix[4]arene as encapsulatory vehicles for platinum(II)-based DNA intercalators2008
Professor Gareth Veal
Julie Errington
Dr Michael Tilby
Professor Alan Boddy
Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours2007
Dr Ian Cowell
Dr Nicola Sunter
Professor Caroline Austin
Emeritus Professor Barbara Durkacz
Dr Michael Tilby
et al.
γH2AX foci form preferentially in euchromatin after ionising-radiation2007
Jessie Jeyapalan
Dr Gabriele Saretzki
Alan Leake
Dr Michael Tilby
Professor Thomas von Zglinicki
et al.
Neuroblastoma cell apoptosis induction after cisplatin treatment is not telomere–dependent2006
Jessie Jeyapalan
Dr Gabriele Saretzki
Alan Leake
Dr Michael Tilby
Professor Thomas von Zglinicki
et al.
Tumour-cell apoptosis after cisplatin treatment is not telomere dependent2006
Annie Parry
Dr Michael Tilby
Professor Dianne Ford
Emerita Professor Suzanne Cholerton
Professor Andrew Pearson
et al.
Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer2005
Dr Ian Cowell
Emeritus Professor Barbara Durkacz
Dr Michael Tilby
Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectsia mutated2005
Dr Emma Meczes
Ali Azim-Araghi
Dr Michael Tilby
Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA2005
Dr Michael Tilby
The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-1362005
Dr Elaine Willmore
Dr Nicola Sunter
Dr Michael Tilby
Professor Graham Jackson
Professor Caroline Austin
et al.
A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia2004
Professor Gareth Veal
Dr Michael Tilby
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia2004
Fiona Errington
Dr Elaine Willmore
Chrysoula Leontiou
Dr Michael Tilby
Professor Caroline Austin
et al.
Differences in the longevity of topo IIα and topo IIβ drug-stabilized cleavable complexes and the relationship to drug sensitivity2004
Dr Michael Tilby
Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis2004
Dr Michael Tilby
Immunohistochemical detection of melphalan-DNA adducts in colon cancer cells in vitro and human colorectal liver tumours in vivo2004
Katherine Gould
Cally Nixon
Dr Michael Tilby
p53 elevation in relation to levels and cytotoxicity of mono- and bifunctional melphalan-DNA adducts2004
Jessie Jeyapalan
Alan Leake
Dr Shaheda Ahmed
Dr Gabriele Saretzki
Dr Michael Tilby
et al.
The role of telomeres in etoposide induced tumor cell death2004
Nidal Boulos
Professor Andrew Pearson
Dr Michael Tilby
Professor John Lunec
1p deleted neuroblastoma cells differentiate following chromosome 1 reintroduction2003
Jessie Jeyapalan
Dr Michael Tilby
Professor Thomas von Zglinicki
Cisplatin induced neuroblastoma cell death and the involvement of telomeres2003
Ali Azim-Araghi
Dr Michael Tilby
Combination of ICP-MS and ion exchange chromatography permits analyses of specific cis-platin DNA modifications formed in cancer cells.2003
Tyrone John
Professor Andrew Pearson
Professor Alan Calvert
Dr Michael Tilby
Determination, by ICP-MS, of background and BBR 3464 induced levels of platinum bound to DNA isolated from blood cells: A comparison of the sensitivity of the Perkin Elmer Sciex Elan 6000 and the thermofinnigan Neptune instruments2003
Dr Michael Tilby
Quantification of DNA adducts in individual cells by immunofluorescence: Effects of variation in DNA conformation2003
Tyrone John
Professor Alan Calvert
Dr Michael Tilby
Sensitive determination of BBR 3464 and cisplatin DNA adduct levels in clinical samples using ICP-MS and PIMMS2003
Tyrone John
Dr Michael Tilby
Characterisation and quantification of DNA adducts formed by the platinum drug BBR 3464.2002
Andrew Jobson
Dr Elaine Willmore
Dr Michael Tilby
Professor Caroline Austin
Characterisation of the roles of Topoisomerase I and II in the mechanism of action of novel anti-tumour agents XR11576 (MLN576) and XR5944 (MLN944)2002
Timothy Cressey
Dr Michael Tilby
Professor Herbie Newell
Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines2002
Dr Elaine Willmore
Fiona Errington
Dr Michael Tilby
Professor Caroline Austin
Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells2002
Nidal Boulos
Professor Andrew Pearson
Dr Michael Tilby
Professor John Lunec
Functional complementation analysis of chromosome 1 in neuroblastoma2002
Dr Elaine Willmore
Dr Michael Tilby
Professor Caroline Austin
Emeritus Professor Barbara Durkacz
Potentiation of topoisomerase II poison cytotoxicity in the K562 human leukaemia cell line by the novel DNA-dependent protein kinase inhibitor NU70262002
Dr Emma Meczes
Professor Andrew Pearson
Professor Caroline Austin
Dr Michael Tilby
Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin2002
Ali Azim-Araghi
Dr Michael Tilby
Structures of atypical PLATINUM-DNA adducts in certain resistant lung cancer lines2002
Dr Peter Middleton
Dr Michael Tilby
Antibody recognition of melphalan adducts characterized using immobilized DNA: Enhanced alkylation of G-rich regions in cells compared to in vitro2001
Dr Emma Meczes
Professor Andrew Pearson
Dr Michael Tilby
Characterisation of the DNA damage recognised by a monoclonal antibody raised against cisplatin-modified DNA2001
Professor Gareth Veal
Dr Cinera Dias
Annie Parry
Julie Errington
Dr Juliet Hale
et al.
Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy2001
Dr Michael Tilby
Measurement of covalent drug-DNA interactions at the nucleotide level in cells at pharmacologically relevant doses2001
Ali Azim-Araghi
Dr Michael Tilby
Mechanisms underlying differences in immunoreactivity of cisplatin DNA adducts formed in certain cancer cells2001
Ali Azim-Araghi
Dr Michael Tilby
Sensitive detection of platinum-bound DNA using ICP-MS and comparison to graphite furnace atomic absorption spectroscopy (GFAAS)2001
Dr Kay Padget
Dr Michael Tilby
Professor Caroline Austin
An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2,1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells2000
Dr Kay Padget
Professor Andrew Pearson
Dr Michael Tilby
Professor Caroline Austin
Camptothecin-stabilised topoisomerase I-DNA complexes in leukaemia cells visualised and quantified in situ by the TARDIS assay (trapped in agarose DNA immunostaining)2000
Professor Penny Lovat
Dr Michael Tilby
Professor Archibald Malcolm
Professor Andrew Pearson
Dr Chris Redfern
et al.
Distinct properties of fenretinide and CD437 lead to synergistic responses with chemotherapeutic reagents2000
Dr Michael Tilby
Evidence for enhanced alkylation of G-rich regions of DNA by melphalan in cells compared to pure solution2000
Ali Azim-Araghi
Dr Michael Tilby
Formation of atypical cisplatin DNA adducts in certain cancer cells2000
Professor Gareth Veal
Dr Cinera Dias
Professor Alan Boddy
Annie Parry
Dr Juliet Hale
et al.
In vitro/in vivo correlations of cisplatin-DNA adduct levels in leucocytes of children2000
Professor Penny Lovat
Dr Michael Tilby
Professor Archibald Malcolm
Professor Andrew Pearson
Dr Chris Redfern
et al.
Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs2000
Timothy Cressey
Dr Michael Tilby
Professor Herbie Newell
Mechanisms of drug specific loss of telomerase activity in testicular cancer cell lines1999
Fiona Errington
Dr Elaine Willmore
Dr Michael Tilby
Professor Caroline Austin
Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: Analysis of cytotoxicity and cleavable complex formation1999
Dr Michael Tilby
Professor Alan Calvert
Professor Herbie Newell
Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels1999
Dr Emma Meczes
Professor Caroline Austin
Professor Andrew Pearson
Dr Michael Tilby
Synergy studies of etoposide and cisplatin action in neuroblastoma cell lines1999
Timothy Cressey
Dr Michael Tilby
Professor Herbie Newell
Comparative effects of cisplatin and melphalan on telomerase activity in a testicular cell line1998
Timothy Cressey
Dr Michael Tilby
Professor Herbie Newell
Comparative effects of DNA damaging drugs on telomerase activity in a testicular cell line1998
Dr Elaine Willmore
Dr Adrian Frank
Dr Kay Padget
Dr Michael Tilby
Professor Caroline Austin
et al.
Etoposide targets topoisomerase IIα and IIβ in leukemic cells: Isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique1998
Professor Alan Boddy
Professor Andrew Pearson
Dr Michael Tilby
Professor Herbie Newell
Cisplatin pharmacokinetics in children with cancer1997
Dr Michael Tilby
Professor Andrew Pearson
Professor Alan Boddy
Professor Herbie Newell
Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy1997
Dr Adrian Frank
Professor Stephen Proctor
Dr Michael Tilby
Detection and quantification of melphalan-DNA adducts at the single cell level in hematopoietic tumor cells1996
Dr Michael Tilby
Effect of quercetin on the genotoxic potential of cisplatin1996
Dr Michael Tilby
Dr Adrian Frank

A monoclonal antibody that recognizes alkali-stabilized melphalan-DNA adducts and its application in immunofluorescence microscopy

1995
Dr Michael Tilby
Differential Sensitivity to the Induction of Apoptosis by Cisplatin in Proliferating and Quiescent Immature Rat Thymocytes Is Independent of the Levels of Drug Accumulation and DNA Adduct Formation1994
Professor Alan Boddy
Professor Andrew Pearson
Dr Michael Tilby
Professor Herbie Newell
The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in pediatric patients: A review.1994
Dr Michael Tilby
Professor Herbie Newell
Application of a sensitive immunoassay to the study of DNA adducts formed in peripheral blood mononuclear cells of patients undergoing high-dose melphalan therapy
1993
Emeritus Professor Andy Hall
Dr Michael Tilby
Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies 1992